« Previous  |  Next »

Vials of 5 Genzyme Drugs for Rare Diseases May Be Contaminated, F.D.A. Says

Vials of five different Genzyme drugs for rare diseases may be contaminated with tiny particles of steel, rubber or fiber that could potentially harm patients, the Food and Drug Administration warned Friday. The warning represented the latest setback ...

From ANDREW POLLACK, The New York Times,  13 Nov 2009

Related Topics: Food and Drug Administration,  Citigroup,  Harvard University

Sanofi Taps Biotech Firm to Bolster Its Pipeline

Increasing its bet on biotechnology, Sanofi-Aventis said it would pay an additional $1 billion over eight years to Regeneron Pharmaceuticals for the discovery of new drugs. The agreement, announced Tuesday, is an extension of one signed in 2007. ...

From ANDREW POLLACK, The New York Times,  10 Nov 2009

Related Topics: Sanofi-Aventis

Questioning a Test for Cancer

Christopher Taylor says he never lasted more than a week when he tried to quit smoking in the past. But it has been four weeks and counting this time, since a genetic test indicated he had a much higher risk of developing lung cancer than the average ...

From ANDREW POLLACK, The New York Times,  6 Nov 2009

Related Topics: Food and Drug Administration,  Duke University,  Johns Hopkins,  Scripps Research Institute

Farmers Skirt Rules on Gene-Altered Crops, Report Says

As many as 25 percent of the American farmers growing genetically engineered corn are no longer complying with federal rules intended to maintain the resistance of the crops to damage from insects, according to a report Thursday from an advocacy group. ...

From ANDREW POLLACK, EcoEarth News,  6 Nov 2009

Related Topics: Environmental Protection Agency

New Drug for H1N1 Flu Offers Hope

Athena Gurno thought her allergies were acting up when she started coughing in early October. But within days, Ms. Gurno, the 30-year-old mother of a young girl, was in a Seattle hospital, close to death from the H1N1 flu. Desperate, her doctors tried ...

From ANDREW POLLACK, The New York Times,  5 Nov 2009

Related Topics: BioCryst Pharmaceuticals, Inc.,  GlaxoSmithKline Inc,  Food and Drug Administration,  Centers for Disease Control and Prevention,  Kleiner Perkins Caufield & Byers

Lupus Drug Shows Promise in New Trial

Human Genome Sciences said early Monday that its experimental drug to treat lupus was effective in its second big clinical trial, raising the chances that the first new treatment for the disease in more than 40 years will make it to market. Doctors, ...

From ANDREW POLLACK, The New York Times,  2 Nov 2009

Related Topics: Human Genome Sciences, Inc.,  GlaxoSmithKline Inc,  Food and Drug Administration

Amgen Accused of Illegal Kickbacks

The biotechnology giant Amgen has been accused by New York and some other states of engaging in illegal kickbacks to promote sales of its anemia drug Aranesp. In a lawsuit filed Friday, the states say that Amgen, in effect, provided free samples to ...

From ANDREW POLLACK, The New York Times,  30 Oct 2009

Related Topics: Amgen Inc.,  Andrew Cuomo,  U.S. Department of Justice,  New England Journal of Medicine,  Johnson & Johnson

California Awards Grants for Research Projects in Nonembryonic Stem Cells

LOS ANGELES In a tacit acknowledgment that the promise of human embryonic stem cells is still far in the future, California’s stem cell research program on Wednesday awarded grants intended to develop therapies using mainly other, less controversial ...

From ANDREW POLLACK, The New York Times,  28 Oct 2009

Related Topics: George W. Bush,  Barack Obama,  Cedars-Sinai Medical Center

F.D.A. Says No, for Now, to an Amgen Bone Drug

Amgen has failed to win approval from the Food and Drug Administration, for now at least, for the bone-strengthening drug that the company has been counting on to propel its growth. The company said Monday morning that the F.D.A. had instead asked for ...

From ANDREW POLLACK, The New York Times,  19 Oct 2009

Related Topics: Amgen Inc.,  Food and Drug Administration

Drug makers chase elusive goal: an effective diet pill

the biggest field, bigger than statins, potentially," said Jack Lief, chief executive of Arena Pharmaceuticals, referring to cholesterol-lowering drugs such as Lipitor, which by itself had $12.4 billion in global sales last year. Americans spent an ...

From ANDREW POLLACK NEW YORK TIMES, The San Jose Mercury News,  17 Oct 2009

Related Topics: Vivus, Inc.,  Arena Pharmaceuticals, Inc.,  Centers for Disease Control and Prevention,  US Food and Drug Administration

« Previous  |  Next »

Who is This?

Help us add to our database, by linking this writer their entry in Wikipedia or Source Watch, or by suggesting that we remove it from our index.

Suggest an Entry